BeOne Medicines Files 2025 Annual Report, Details GAAP Differences

BeOne Medicines Ltd. filed its 2025 Annual Report with the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange. The report, prepared under PRC GAAP, includes additional financial information such as gross profit margin, R&D expenses by product, and production, sales, and inventory units for the year ended December 31, 2025. The company also detailed key differences between financial information prepared under PRC GAAP and U.S. GAAP, specifically regarding share-based compensation and leasing accounting.